Corvus Pharmaceuticals, Inc. (CRVS) Income Statement

The absence of revenue is consistent with a clinical-stage biotech, but the trajectory of operating losses is concerning. R&D spending has more than tripled from $4.1M to $16.0M over the same timeframe, indicating an aggressive ramp in clinical trial activity. However, with cash reserves of only $4.58M, this pace of spending is unsustainable without near-term financing or partnership milestones.

The cost structure is heavily weighted toward R&D, which is typical for a clinical-stage company but highlights the high fixed costs of trial execution. SG&A has grown modestly from $2.2M to $3.3M, suggesting disciplined overhead management. The rapid escalation in R&D spending, however, suggests that the company is investing heavily in late-stage trials, which may be necessary to reach data readouts but also accelerates cash consumption.

The lack of revenue means that every dollar of expense directly increases operating losses. The fact that R&D spending has grown at a much faster rate than SG&A suggests that the company is prioritizing clinical advancement over cost containment. This is a double-edged sword: it may be necessary to reach value-inflecting milestones, but it also means that the company's cash runway is shortening at an accelerating pace.

The 2025Q1 net income spike is a clear outlier in an otherwise consistent pattern of increasing losses. This suggests that the company's fundamental financial trajectory is one of escalating burn, and the positive quarter should not be interpreted as a turning point. The subsequent quarters show a return to and acceleration of losses, indicating that the underlying operational performance has not improved.